Land: Kanada
Språk: engelska
Källa: Health Canada
SODIUM CHLORIDE
MCGAW INC.
B05XA03
SODIUM CHLORIDE
9MG
LIQUID
SODIUM CHLORIDE 9MG
INTRAVENOUS
500 ML
Ethical
REPLACEMENT PREPARATIONS
Active ingredient group (AIG) number: 0100053002; AHFS:
CANCELLED POST MARKET
1998-04-08
_0.9% Sodium Chloride Injection USP Prescribing Information _ _Page 1 of 10_ PRESCRIBING INFORMATION 0.9% SODIUM CHLORIDE INJECTION USP Solution, Intravenous IV Fluid and Electrolyte Replenisher B. BRAUN MEDICAL INC. Date of Preparation: 824 Twelfth Avenue August 24, 2020 Bethlehem, PA 18018-3524 USA Distributed by: B. BRAUN OF CANADA, LTD. 2000 Ellesmere Road, Unit 16 Scarborough, Ontario M1H 2W4 Submission Control No: 235120 _ _ _0.9% Sodium Chloride Injection USP Prescribing Information _ _Page 2 of 10_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ......................................................... 3 1 INDICATIONS ............................................................................................................... 3 1.1 PEDIATRICS ............................................................................................................ 3 1.2 GERIATRICS ............................................................................................................ 3 2 CONTRAINDICATIONS .............................................................................................. 3 3 DOSAGE AND ADMINISTRATION ........................................................................... 3 3.1 DOSING CONSIDERATIONS .................................................................................... 3 3.2 RECOMMENDED DOSE AND DOSAGE ADJUSTMENT ........................................... 4 3.3 ADMINISTRATION ................................................................................................... 4 4 OVERDOSAGE ............................................................................................................ 5 5 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING ............... 5 6 WARNINGS AND PRECAUTIONS ............................................................................ 6 6.1 SPECIAL POPULATIONS .......................................................................................... 7 6.1.1 PREGNANT WOMEN ..................................................... Läs hela dokumentet